Study shows mobility improved by CBD for those living with multiple sclerosis


Multiple Sclerosis is disease of the central nervous system that affects an estimated 1 million people in the United States. This inflammatory condition is progressive, stripping the protective myelin coating from nerves, which interrupts electrical signaling and leads to hardening of the nerves where myelin is lost. ENFLEUR would like to share a hopeful 2018 study published in the peer-reviewed journal Frontiers in Neurology showing that CBD can potentially improve mobility for those living with MS because CBD may have beneficial therapeutic effects on the symptoms of MS that contribute to reduced mobility. 

The study reports that data indicates that cannabis with a high CBD:THC ratio reduces both pain and muscle spasticity in MS, while some studies suggest that cannabinoids may reduce inflammation and pain, and that CBD has exhibited dose-dependent antidepressant-like effects in animal models. By reducing inflammation, CBD also has the ability to positively impact MS-related fatigue. The study also notes that CBD is anti-inflammatory, antioxidative, antiemetic, antipsychotic, and neuroprotective, and has no noted negative effects on psychomotor or psychological functions.

Since no serious drug interactions have been seen with CBD in combination with other drugs, and because acute doses (up to 1,500mg daily) of CBD are shown to be well-tolerated, those living with MS may want to consult with their doctor about incorporating a high-quality, high-potency CBD supplement into their wellness routine. 

Why does this matter? CBD has shown potential in mediating the symptoms of MS that lead to reduced mobility.